The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Discover the hidden history of breath and its vital role in human life through insightful research and groundbreaking ...

The Center for Biological Diversity sued the Trump administration today for failing to release the names of fossil fuel companies and other polluters seeking exemptions from life-saving Clean Air Act ...

Naturepedic says that from food packaging to cleaning products, to personal care items and even crib mattresses, harmful chemicals have quietly worked their way into everyday life, and are polluting ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma Management and Prevention guidance report. Chair of the GINA Dissemination Working ...